Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial
Authors: Zweck Elric , Hassager Christian , Beske Rasmus P. , Jensen Lisette O. , Eiskjær Hans , Mangner Norman , Polzin Amin , Schulze P. Christian , Skurk Carsten , Nordbeck Peter , Clemmensen Peter , Panoulas Vasileios , Zimmer Sebastian , Schäfer Andreas , Kelm Malte , Engstrøm Thomas , Holmvang Lene , Junker Anders , Schmidt Henrik , Terkelsen Christian J. , Linke Axel , Westenfeld Ralf , Møller Jacob E. , Møller Jacob Eifer , Jensen Lisette Okkels , Junker Anders , Veien Karsten Tange , Udesen Nanna Louise Junker , Ravn Hanne Berg , Lassen Jens Flensted , Wachtell Kristian , Schmidt Henrik , Hassager Christian , Engstrøm Thomas , Holmvang Lene , Kjaergaard Jesper , Sørensen Rikke , Lønborg Jacob , Fryldand Martin , Beske Rasmus Paulin , Boesgaard Søren , Eiskjær Hans , Christensen Steffen , Christiansen Evald Høj , Christensen Steffen , Terkelsen Christian Juhl , Schäfer Andreas , Linke Axel , Woitek Felix J. , Hommel Jennifer , Mangner Norman , Polzin Amin , Westenfeld Ralf , Schulze Christian , Moebius-Winkler Sven , Skurk Carsten , Nordbeck Peter , Clemmensen Peter , Westermann Dirk , Panoulas Vasileios , Zimmer Sebastian , Werner Nikos , De Haas Inge 
Published: October 2024

BACKGROUND:

In DanGer Shock (the Danish–German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment–elevation myocardial infarction–related cardiogenic shock led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed.

METHODS:

In this international, randomized, open-label, multicenter trial, 355 adult patients with ST-segment–elevation myocardial infarction–related cardiogenic shock were randomized to mAFP (n=179) or standard care alone (n=176). AKI was defined according to RIFLE criteria (Risk, Injury, Failure, Loss, and End-stage kidney disease) and assessed using logistic regression models. Use of RRT was assessed accounting for the competing risk of death using Fine-Gray subdistribution hazard models.

RESULTS:

AKI (RIFLE ≥1) was recorded in 110 patients (61%) in the mAFP group and 79 patients (45%) in the control group (
P
<0.01); RRT was used in 75 (42%) and 47 (27%) patients, respectively (
P
<0.01). About two-thirds of the RRTs were initiated within the first 24 hours from admission (n=48 [64%] in the mAFP group and n=31 [66%] in the control group). Occurrence of AKI and RRT were associated with higher 180-day mortality in both study arms. At 180 days, all patients alive were free of RRT. mAFP use was associated with higher rates of RRT, even when accounting for competing risk of death (subdistribution hazard, 1.67 [1.18–2.35]). This association was largely consistent among prespecified subgroups. Allocation to mAFP was associated with lower 180-day mortality irrespective of AKI or RRT (
P
interaction
=0.84). Relevant predictors of AKI in both groups comprised reduced left ventricular ejection fraction, baseline kidney function, shock severity, bleeding events, and positive fluid balance. Predictors of AKI specific to mAFP were suction events, higher pump speed, and longer duration of support.

CONCLUSIONS:

Shock severity, allocation to mAFP, and device-related complications were associated with an increased risk of AKI. AKI was generally associated with higher mortality, but the allocation to mAFP consistently led to lower mortality rates at 180 days irrespective of the occurrence of AKI with or without RRT initiation.

REGISTRATION:

URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT01633502.